Published in Breast Cancer Res on December 08, 2011
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol (2014) 5.61
Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. J Clin Oncol (2015) 2.54
The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. PLoS One (2014) 1.64
Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget (2015) 1.62
Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy. Oncoimmunology (2014) 1.60
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A (2013) 1.54
Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. JAMA Oncol (2016) 1.54
Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer (2013) 1.50
Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer (2012) 1.33
The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. Br J Cancer (2014) 1.30
Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol (2015) 1.22
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol (2016) 1.18
Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics. Neoplasia (2013) 1.17
Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res (2014) 1.17
Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. Ther Adv Med Oncol (2013) 1.15
Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res (2014) 1.07
PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget (2015) 1.04
Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther (2012) 1.03
NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer. PLoS One (2012) 0.94
Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med (2015) 0.92
Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers. Breast Cancer Res Treat (2013) 0.91
High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer. BMC Cancer (2014) 0.89
Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer. J Pathol Transl Med (2015) 0.88
Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. BMC Cancer (2015) 0.88
Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials. Oncotarget (2016) 0.88
Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. Hum Pathol (2013) 0.88
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Mod Pathol (2016) 0.85
Profiling the immune stromal interface in breast cancer and its potential for clinical impact. Breast Care (Basel) (2012) 0.85
A role for T-lymphocytes in human breast cancer and in canine mammary tumors. Biomed Res Int (2014) 0.85
Pilot study of p62 DNA vaccine in dogs with mammary tumors. Oncotarget (2014) 0.84
Differential peripheral blood gene expression profile based on Her2 expression on primary tumors of breast cancer patients. PLoS One (2014) 0.83
Dual roles for immune metagenes in breast cancer prognosis and therapy prediction. Genome Med (2014) 0.82
Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis. Clin Transl Oncol (2015) 0.82
Exercise training and immune crosstalk in breast cancer microenvironment: exploring the paradigms of exercise-induced immune modulation and exercise-induced myokines. Am J Transl Res (2014) 0.81
Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer. Breast Care (Basel) (2016) 0.81
Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis. Oncotarget (2016) 0.80
Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes. Cancer Immunol Res (2016) 0.80
Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Res (2016) 0.80
Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer. BMC Cancer (2016) 0.79
Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. Breast Cancer Res (2015) 0.79
The prognostic value of systemic and local inflammation in patients with laryngeal squamous cell carcinoma. Onco Targets Ther (2016) 0.78
Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment. Adv Cancer Res (2015) 0.78
Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer. Neoplasia (2014) 0.78
CD74 and intratumoral immune response in breast cancer. Oncotarget (2017) 0.77
Similar lymphocytic infiltration pattern in primary breast cancer and their corresponding distant metastases. Oncoimmunology (2016) 0.77
Breast cancer survival among young women: a review of the role of modifiable lifestyle factors. Cancer Causes Control (2016) 0.77
Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy. Cancer Biol Ther (2017) 0.76
Defining lymphocyte-predominant breast cancer by the proportion of lymphocyte-rich stroma and its significance in routine histopathological diagnosis. Pathol Int (2015) 0.76
Association between Chemotherapy-Response Assays and Subsets of Tumor-Infiltrating Lymphocytes in Gastric Cancer: A Pilot Study. J Gastric Cancer (2015) 0.76
Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis. Oncoimmunology (2015) 0.76
Can pharmacological receptor tyrosine kinase inhibitors sensitize poor outcome breast tumors to immune-based therapies? Front Oncol (2013) 0.76
Immune profiling in human breast cancer using high-sensitivity detection and analysis techniques. JRSM Open (2015) 0.76
The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression. Nat Commun (2017) 0.75
Towards tumor immunodiagnostics. Ann Transl Med (2016) 0.75
The prognostic and predictive value of the lymphocyte to monocyte ratio in luminal-type breast cancer patients treated with CEF chemotherapy. Oncotarget (2016) 0.75
Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer. Oncotarget (2017) 0.75
Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study. PLoS Med (2016) 0.75
Immunotherapy for Breast Cancer: What Are We Missing? Clin Cancer Res (2017) 0.75
Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis. ESMO Open (2016) 0.75
Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis. PLoS Med (2016) 0.75
Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer. Cancer Res Treat (2016) 0.75
Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy. Breast Care (Basel) (2016) 0.75
Baseline blood immunological profiling differentiates between Her2-breast cancer molecular subtypes: implications for immunomediated mechanisms of treatment response. Onco Targets Ther (2015) 0.75
Comparison of Tumour-infiltrating Lymphocytes between Primary and Metastatic Tumours in Breast Cancer Patients. Cancer Sci (2016) 0.75
SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors. Oncotarget (2016) 0.75
Tumor-infiltrating lymphocytes predict prognosis of breast cancer patients treated with anti-Her-2 therapy. Oncotarget (2016) 0.75
Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer. J Immunol Res (2016) 0.75
A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC). Clin Cancer Res (2017) 0.75
Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling. PLoS One (2017) 0.75
Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer. Med Mol Morphol (2017) 0.75
Identification of candidate genes associated with triple negative breast cancer. Genes Cancer (2017) 0.75
Predictive and prognostic significance of CD8(+) tumor-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapy. Oncol Lett (2017) 0.75
Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study. Int J Mol Sci (2017) 0.75
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol (2009) 7.21
Immunological aspects of cancer chemotherapy. Nat Rev Immunol (2008) 6.61
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol (2006) 6.23
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res (2008) 5.88
The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res (2008) 5.69
A polyadenylate binding protein localized to the granules of cytolytic lymphocytes induces DNA fragmentation in target cells. Cell (1991) 5.65
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood (2004) 5.02
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol (2004) 5.02
Triple negative tumours: a critical review. Histopathology (2008) 4.94
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol (2007) 4.33
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 4.32
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest (2010) 3.97
Retracted Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol (2007) 3.67
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol (2006) 3.58
Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med (2005) 3.22
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer (2006) 2.75
Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med (2010) 2.62
High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res (2007) 2.48
Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res (2004) 2.46
Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res (2008) 2.37
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res (2009) 2.26
A monoclonal antibody reactive with a 15-kDa cytoplasmic granule-associated protein defines a subpopulation of CD8+ T lymphocytes. J Immunol (1990) 2.24
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A (2007) 2.11
Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res (2007) 1.95
Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer (2004) 1.87
Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res (2008) 1.82
Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res (2001) 1.76
Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol (2006) 1.52
Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients. Leuk Lymphoma (2005) 1.47
The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev (2008) 1.43
Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer. Breast Cancer Res Treat (2008) 1.42
Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients. Curr Opin Oncol (2010) 1.31
Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma. Cancer Invest (2008) 1.30
Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res Treat (2008) 1.24
Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS One (2009) 1.24
Role of anthracyclines in the treatment of early breast cancer. J Clin Oncol (2009) 1.16
The presence of CD56/CD16 in T-cell acute lymphoblastic leukaemia correlates with the expression of cytotoxic molecules and is associated with worse response to treatment. Br J Haematol (2008) 1.16
Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer. PLoS One (2008) 1.14
Chemoimmunotherapy. Cancer J (2010) 1.13
NF-κB-dependent cytokine secretion controls Fas expression on chemotherapy-induced premature senescent tumor cells. Oncogene (2011) 1.07
Predicting anthracycline benefit: have we made any progress? Curr Opin Oncol (2009) 0.95
Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways. J Immunol (2004) 0.94
Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge. Oncogene (2010) 0.93
CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas Ligand, and killing inhibitory receptors and their relationship with clinical behavior. J Clin Oncol (2001) 0.90
Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet (2002) 3.89
Time to stop progesterone receptor testing in breast cancer management. J Clin Oncol (2004) 3.33
Profiling the T-cell receptor beta-chain repertoire by massively parallel sequencing. Genome Res (2009) 3.29
Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res (2003) 2.37
The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res (2012) 2.37
Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One (2009) 2.36
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res (2014) 2.03
Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol (2013) 1.99
Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS One (2008) 1.93
Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res (2007) 1.82
Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community-based population analysis. Int J Radiat Oncol Biol Phys (2003) 1.75
The autophagy protein LC3A correlates with hypoxia and is a prognostic marker of patient survival in clear cell ovarian cancer. J Pathol (2012) 1.72
Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res (2002) 1.71
Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin Cancer Res (2003) 1.67
Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol (2003) 1.67
CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res (2012) 1.64
FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism. Mol Cell Biol (2004) 1.63
Validation of a web-based predictive nomogram for ipsilateral breast tumor recurrence after breast conserving therapy. J Clin Oncol (2010) 1.59
Is mastectomy superior to breast-conserving treatment for young women? Int J Radiat Oncol Biol Phys (2007) 1.58
Transcription-induced chromatin remodeling at the c-myc gene involves the local exchange of histone H2A.Z. J Biol Chem (2005) 1.56
ESRRA-C11orf20 is a recurrent gene fusion in serous ovarian carcinoma. PLoS Biol (2011) 1.53
A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood (2011) 1.51
Intraoperative accelerated partial breast irradiation: caution still warranted. Int J Radiat Oncol Biol Phys (2014) 1.42
Does a three-field electron/minitangent photon technique offer dosimetric advantages to a multifield, photon-only technique for accelerated partial breast irradiation? Am J Clin Oncol (2010) 1.39
S100 proteins and their influence on pro-survival pathways in cancer. Biochem Cell Biol (2004) 1.37
Target volume delineation for partial breast radiotherapy planning: clinical characteristics associated with low interobserver concordance. Int J Radiat Oncol Biol Phys (2007) 1.34
A low carbohydrate, high protein diet slows tumor growth and prevents cancer initiation. Cancer Res (2011) 1.33
Clinical significance of estrogen receptor phosphorylation. Endocr Relat Cancer (2011) 1.33
Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res (2013) 1.30
A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients. Clin Cancer Res (2010) 1.30
Profiling model T-cell metagenomes with short reads. Bioinformatics (2009) 1.29
Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis. J Clin Oncol (2005) 1.24
Psoriasin (S100A7) expression is associated with poor outcome in estrogen receptor-negative invasive breast cancer. Clin Cancer Res (2003) 1.23
Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q. Int J Cancer (2003) 1.22
Psoriasin interacts with Jab1 and influences breast cancer progression. Cancer Res (2003) 1.20
Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. Clin Cancer Res (2013) 1.18
NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis. Oncogene (2005) 1.16
Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes. J Transl Med (2012) 1.16
BRCA1 and c-Myc associate to transcriptionally repress psoriasin, a DNA damage-inducible gene. Cancer Res (2005) 1.15
Influence of evolution in tumor biobanking on the interpretation of translational research. Cancer Epidemiol Biomarkers Prev (2008) 1.15
Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease. J Pathol (2012) 1.15
The S100A7-c-Jun activation domain binding protein 1 pathway enhances prosurvival pathways in breast cancer. Cancer Res (2005) 1.15
Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer. PLoS One (2008) 1.14
S100A7 and the progression of breast cancer. Breast Cancer Res (2004) 1.14
A population-based study of the fractionation of postlumpectomy breast radiation therapy. In regard to Ashworth et al. Int J Radiat Oncol Biol Phys (2013) 1.13
BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol (2012) 1.12
Necrosis and hypoxia in invasive breast carcinoma. Breast Cancer Res Treat (2003) 1.12
Consistency in seroma contouring for partial breast radiotherapy: impact of guidelines. Int J Radiat Oncol Biol Phys (2006) 1.11
Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients. Int Immunol (2006) 1.11
Identification of a novel breast- and salivary gland-specific, mucin-like gene strongly expressed in normal and tumor human mammary epithelium. Cancer Res (2002) 1.10
Intervals longer than 20 weeks from breast-conserving surgery to radiation therapy are associated with inferior outcome for women with early-stage breast cancer who are not receiving chemotherapy. J Clin Oncol (2008) 1.08
The hypoxia-regulated transcription factor DEC1 (Stra13, SHARP-2) and its expression in human tissues and tumours. J Pathol (2004) 1.08
Preliminary reliability and validity testing of a new Skin Toxicity Assessment Tool (STAT) in breast cancer patients undergoing radiotherapy. Am J Clin Oncol (2004) 1.07
STAT5 is essential for Akt/p70S6 kinase activity during IL-2-induced lymphocyte proliferation. J Immunol (2007) 1.07
Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia. Mol Cancer (2010) 1.06
Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection. Cancer Res (2006) 1.06
Psoriasin (S100A7) expression is altered during skin tumorigenesis. BMC Dermatol (2003) 1.06
Estrogen receptor-alpha phosphorylated at Ser118 is present at the promoters of estrogen-regulated genes and is not altered due to HER-2 overexpression. Cancer Res (2006) 1.05
S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast. Breast Cancer Res (2004) 1.04
Identification of new human coding steroid receptor RNA activator isoforms. Biochem Biophys Res Commun (2003) 1.04
Immunohistochemical validation of multiple phospho-specific epitopes for estrogen receptor alpha (ERalpha) in tissue microarrays of ERalpha positive human breast carcinomas. Breast Cancer Res Treat (2008) 1.03
Permission to contact (PTC)--a strategy to enhance patient engagement in translational research. Biopreserv Biobank (2013) 1.03
Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor alpha in human breast carcinoma. Clin Cancer Res (2004) 1.03
Analysis of gene expression in ductal carcinoma in situ of the breast. Clin Cancer Res (2002) 1.01
Enhanced signaling through the IL-2 receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ T cells rather than promotion of cell death. Proc Natl Acad Sci U S A (2002) 0.99
Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer? Endocr Relat Cancer (2006) 0.98
Estrogen receptor alpha negative breast cancer patients: estrogen receptor beta as a therapeutic target. J Steroid Biochem Mol Biol (2007) 0.98
Timing of consent for the research use of surgically removed tissue: is postoperative consenting acceptable? Cancer (2009) 0.97
A permissive role for phosphatidylinositol 3-kinase in the Stat5-mediated expression of cyclin D2 by the interleukin-2 receptor. J Biol Chem (2003) 0.97
When is CT-based postoperative seroma most useful to plan partial breast radiotherapy? Evaluation of clinical factors affecting seroma volume and clarity. Int J Radiat Oncol Biol Phys (2008) 0.97
Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype. Virchows Arch (2009) 0.96
Postmastectomy radiation therapy: who needs it? J Clin Oncol (2004) 0.96
Biospecimen use correlates with emerging techniques in cancer research: impact on planning future biobanks. Biopreserv Biobank (2012) 0.95
Estrogen receptor-beta regulates psoriasin (S100A7) in human breast cancer. Breast Cancer Res Treat (2006) 0.94
Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C). Vaccine (2010) 0.93
RanBPM interacts with psoriasin in vitro and their expression correlates with specific clinical features in vivo in breast cancer. BMC Cancer (2002) 0.93
Impact of a Permission to Contact (PTC) platform on biobank enrollment and efficiency. Biopreserv Biobank (2013) 0.93
Can locoregional treatment of the primary tumor improve outcomes for women with stage IV breast cancer at diagnosis? Int J Radiat Oncol Biol Phys (2012) 0.93
3D ultrasound can contribute to planning CT to define the target for partial breast radiotherapy. Int J Radiat Oncol Biol Phys (2008) 0.93
Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir. Int J Radiat Oncol Biol Phys (2011) 0.92
Expression analysis of the mouse S100A7/psoriasin gene in skin inflammation and mammary tumorigenesis. BMC Cancer (2005) 0.92
A phosphorylation code for oestrogen receptor-alpha predicts clinical outcome to endocrine therapy in breast cancer. Endocr Relat Cancer (2010) 0.92
Primary cutaneous diffuse large B-cell lymphoma: a clinicopathologic study of 15 cases. Am J Clin Pathol (2002) 0.92
The relevance of phosphorylated forms of estrogen receptor in human breast cancer in vivo. J Steroid Biochem Mol Biol (2009) 0.91
Does the intent to irradiate the internal mammary nodes impact survival in women with breast cancer? A population-based analysis in British Columbia. Int J Radiat Oncol Biol Phys (2012) 0.91
Tumor-infiltrating B cells and T cells: Working together to promote patient survival. Oncoimmunology (2012) 0.91
Differential expression of claudin 1, 3, and 4 during normal mammary gland development in the mouse. DNA Cell Biol (2006) 0.90
Spontaneous mammary tumors differ widely in their inherent sensitivity to adoptively transferred T cells. Cancer Res (2007) 0.90